Skip to content
Screener

ANI Pharmaceuticals ANIP Shares (Diluted)

Shares (Diluted) at other companies

Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
328.1M+1.8%
Viatris logo
ViatrisVTRS
1.2B-0.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
28.7M-6.4%
ALN
Alnylam PharmaceuticalsALNY
138.3M+5.9%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
31.5M+17.3%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
133.5M-2.9%

Other financials

Income statement

See full
Revenue$266.0M+25.9%
Gross profit$165.9M+21.3%
Operating income$40.5M+191%
Net income$24.7M+189%
EPS (diluted)$1.05+192%

Balance sheet

See full
Cash & equivalents$360.2M+65.4%
Total debt$301.5M-4.2%
Total equity$597.2M+36.7%
Total assets$1.5B+11.3%

Cash flow

See full
Operating cash flow$56.7M-25.3%
CapEx$3.1M-23.9%
Free cash flow$53.6M-25.3%

Valuation

See full
Market cap$1.88B+25.6%
Enterprise value$1.82B+14.3%
P/E17.3×
P/S1.9×-0.1×

Profitability

See full
Gross margin60.4%-0.7pp
Operating margin15.4%
Net margin11.1%+10.0pp
FCF margin17.7%+0.9pp

Returns & leverage

See full
Return on equity21%+19.1pp
Debt / equity0.5×-0.2×
Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 7:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001023024-26-000069
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net Income$24,711$8,549$54,203$24,230
Dividends on Series A Convertible Preferred Stock(407)(813)
Net Income Available to Common Shareholders$24,711$8,142$54,203$23,417
Basic and Diluted Income Per Share:
Basic Income Per Share$1.09$0.37$2.40$1.07
Diluted Income Per Share$1.05$0.36$2.32$1.05
Basic Weighted-Average Shares Outstanding21,15819,83421,03619,721
Diluted Weighted-Average Shares Outstanding21,91520,30821,78520,177

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's shares (diluted)?
ANI Pharmaceuticals (ANIP) reported shares (diluted) of 21.9M in Q2 2026.
How has ANI Pharmaceuticals's shares (diluted) changed year-over-year?
ANI Pharmaceuticals's shares (diluted) increased by 7.9% year-over-year, from 20.3M to 21.9M.
What is the long-term trend for ANI Pharmaceuticals's shares (diluted)?
Over 4 years (2021 to 2025), ANI Pharmaceuticals's shares (diluted) has grown at a 14.1% compound annual growth rate (CAGR), from 48.8M to 82.7M.
What does shares (diluted) mean?
The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.

Ask your AI about ANI Pharmaceuticals's shares (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude